Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine

Manish Pratap Singh; Sandhya Rai; Ashutosh Pandey; Nand K. Singh; Sameer Srivastava

doi:10.1016/j.gendis.2019.10.013

您当前的位置：

首页 >

文章列表页 >

Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine

Review article | 更新时间：2022-06-24

- Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
- Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
- Genes & Diseases 2021年8卷第2期
- 作者机构：
  
  Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, UP,India,211004
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2019.10.013
  中图分类号：
- 纸质出版日期：2021，
  
  网络出版日期：2021-3-1，
扫描看全文
Manish Pratap Singh, Sandhya Rai, Ashutosh Pandey, 等. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine[J]. Genes & Diseases, 2021,8(2).

Manish Pratap Singh, Sandhya Rai, Ashutosh Pandey, et al. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine[J]. Genes & Diseases, 2021,8(2).
Manish Pratap Singh, Sandhya Rai, Ashutosh Pandey, 等. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine[J]. Genes & Diseases, 2021,8(2). DOI： 10.1016/j.gendis.2019.10.013.

Manish Pratap Singh, Sandhya Rai, Ashutosh Pandey, et al. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine[J]. Genes & Diseases, 2021,8(2). DOI： 10.1016/j.gendis.2019.10.013.

摘要

Abstract

Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings. Current treatment strategies in colorectal cancer are largely ‘one drug fit all’ model for patients that display same pathological conditions. However

CRC is a very heterogenous set of malignancy that does not support for above criteria. Each subtype displays different pathological and genetic signatures. Based on these features

therapeutic stratification for individual patients may be designed

which may ultimately lead to improved therapeutic outcomes. In this comprehensive review

we have attempted to briefly outline major CRC pathways. A detailed overview of molecular subtypes and their clinical significance has been discussed. Present and future methods

governing CRC subtyping in the era of personalized therapy with a special emphasis on CMS subtypes of CRC has been reviewed. Together

discovery and validation of new CRC patient stratification methods

screening for novel therapeutic targets

and enhanced diagnosis of CRC may improve the treatment outcome.

关键词

Keywords

BiomarkersCMS subtypesImmunotherapyMolecular screeningPersonalized medicine

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Cancer organoids: A platform in basic and translational research

DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy